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Abstract
Background: Sharing of tissue samples for research and disease surveillance purposes has become increasingly
important. While it is clear that this is an area of intense, international controversy, there is an absence of data
about what researchers themselves and those involved in the transfer of samples think about these issues,
particularly in developing countries.
Methods: A survey was carried out in a number of Asian countries and in Egypt to explore what researchers and
others involved in research, storage and transfer of human tissue samples thought about some of the issues
related to sharing of such samples.
Results: The results demonstrated broad agreement with the positions taken by developing countries in the
current debate, favoring quite severe restrictions on the use of samples by developed countries.
Conclusions: It is recommended that an international agreement is developed on what conditions should be
attached to any sharing of human tissue samples across borders.
Background
Sharing of tissue samples for research and disease sur-
veillance purposes has become increasingly important.
The Global Influenza Surveillance Network coordinated
by the World Health Organization (WHO) is one such
example. In 2007, however, after Indonesia refused to
share its H5N1 samples without a legally binding agree-
ment concerning benefit arrangements and appropriate
attention to Intellectual Property (IP) rights (patent)
issues within the network, WHO initiated a discussion
regarding a Pandemic Influenza Preparedness Frame-
work (PIP Framework) to address these concerns [1].
No agreement was reached regarding key issues during
deliberations at the World Health Assembly in 2009.
The main points of contention are whether a Standard
Material Transfer Agreement (SMTA) for sharing of
samples within this network should include specific ben-
efit arrangements as conditions of transfer of samples
and whether recipients of samples should be free to pur-
sue IP rights to any products developed using the sam-
ples obtained through the network. The developed
country position is basically that SMTAs should not
cover these two issues, whereas the developing country
position is that it should.
The Convention on Biological Diversity, which came
into force in 1993, contains a section on right of access
to genetic resources and the benefits from their use
(Article 15). The convention establishes a sovereign
right of nations to the genetic resources within their ter-
ritories and fair and equitable access to benefits arising
out of research and commercial use using such
resources. Developing countries have referred to this
Convention in support of their demand for legally bind-
ing agreements regarding transfer of samples, but devel-
oped countries have maintained that the Convention is
not applicable to the case of influenza viruses. The case
is complicated because it is recognized that the Conven-
tion on Biological Diversity does not apply to human
genetic resources, and the status of flu viruses contained
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any medium, provided the original work is properly cited.in human tissue is unclear. Currently there is an attempt
to develop an International Regime on Access and Bene-
fit Sharing with a draft text expected from a working
group sometime in 2010. The issue of benefit sharing in
the context of the Convention on Biological Diversity
has received quite a bit of attention also in the bioethics
literature [2], and there are a few examples of successful
negotiations with sponsors for specific benefits from the
commercial development of genetic resources [3]. It is
unclear, however, whether such examples contain useful
lessons for negotiations of access and benefits within
more basic research networks. The fact that it has taken
a considerable period of time to even develop a draft for
an International Regime on Access and Benefit Sharing
shows that there is considerable disagreements among
the parties.
Sharing of tissue samples among research groups also
raises the issue of deciding what research to do on sam-
ple collections and who should be authors on papers
from such research. Since only a finite number of
research projects can be carried out on any given collec-
tion of samples, there has to be an agreed on policy
with regard to how one should decide what research to
approve. Although a number of tissue banks have
adopted decision making procedures, there is little gui-
dance and much uncertainty about what substantive cri-
teria should be used to make such decisions [4-6]. This
has also been an area of controversy in the case of the
PIP Framework.
While it is clear that this is an area of intense, interna-
tional controversy, there is an absence of data about
what researchers themselves and those involved in the
transfer of samples think about these issues, particularly
in developing countries. In order to begin to explore
these issues we carried out a survey (Additional file 1)
in a number of Asian countries and in Egypt. The aim
of the survey was to identify what policy makers,
researchers and members of research ethics review com-
mittees thought about key issues related to access to
stored tissue samples.
Methods
Survey countries and populations
The target populations were enrolled from sites in
China, Egypt, India, Japan, and South Korea. The coun-
tries were chosen based on an existing network of
researchers in these countries. The potential participants
were selected from the following four groups, 1)
researchers who have been or are conducting research
on human biological samples, 2) collectors who have
been or are collecting human biological samples, 3)
ethics committee members who are currently sitting as
a research ethics review board member, and 4) policy-
makers who have been involved in setting an
institution’s policy with regard to research on stored tis-
sue samples. Local PIs in each country determined the
way of enrolling research participants, and therefore the
participants other than the Japanese participants who
were enrolled through cluster randomization, were a
sample of convenience.
Questionnaire
For details regarding the questionnaire development, see
the publication of results from the first part of the sur-
vey on issues related to informed consent [7]. The ques-
tionnaire was translated and administered in the local
language. The part related to international transfer of
samples contained the following four survey domains
which assess participant attitudes towards:
1. Decisions regarding location of samples
2. Decision making procedures for choice of research
on samples
3. Issues related to authorship of publications
4. Issues related to intellectual property rights
Most of questions were in the form of a binary choice
or a five-point Likert scale ranging from 1 (strongly dis-
agree) to 5 (strongly agree). The survey was conducted
between 2005 and 2008. The term “local scientist” refers
to scientists who live and oversee research and collec-
tion in the country where samples are taken. The term
“foreign collaborating scientist” refers to scientists from
other countries.
Human subjects approval
The ethics approval at the US National Institutes of
Health was formally exempted by Office of Human Sub-
jects Research (No. 3074). Each collaborating local PI
obtained an ethics approval from a research ethics com-
mittee of her own institution.
Results
The total number of valid responses obtained was 154
in China, 186 in Egypt, 127 in India, 864 in Japan, and
105 in Korea. The response rate for Japan in which
the questionnaires were sent out to the potential par-
ticipants of randomly selected institutions was
approximately 33%. For the other three countries
where the potential participants were of a sample of
convenience, no detailed data about response rate
were available.
Demographic characteristics
Compared to the other three countries, the respon-
dents in India and Japan were relatively older. Most of
the respondents except the Chinese had doctoral
degrees. Among all of the respondents, there were 341
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a half of the respondents in each country reported that
they were currently involved in policy making pro-
cesses concerning research. Other than the Japanese
respondents, a majority reported that they were con-
ducting research on stored human biological samples
(from 57.5% in India to 89.6% in China) and collecting
them for future use in research (from 56.7% in India
to 67.2% in Egypt), whereas doing so among the Japa-
nese respondents were only 35.1% and 29.1%, respec-
tively. For additional details regarding demographics
see the companion publication [7].
Involvement in the use of Material Transfer Agreements
Most of our respondents had not been involved at all in
the use of a Material Transfer Agreement (MTA) for
the transfer of biological samples (81.9% of respondents,
varying from lows of 47.4% in China and 61.4% in India
to a high of 93.3% in Korea). In China and India most
of those who had been involved in MTAs had been
involved in the development of the MTA itself or the
transfer of samples (27.3% for China and 15% for India,
and 27.3% for China and 26.8% for India respectively).
Intellectual property, royalties and benefit arrangements
(Table 1)
The respondents were asked about how intellectual
property rights related to research on the samples
should be handled. There was general agreement that
royalties should be shared with the local scientists, ran-
ging from a high of 87.1% in Egypt, to 49.8% in Japan.
Smaller percentages in all countries agreed that royalties
should be shared with the local population, ranging
from 78.7% in India to 35% in Japan. There was also a
general agreement that the population from which the
samples were taken should given access to products,
such as a vaccine or new drug, that arise from research
on the samples, ranging from 47.2% in Japan to a high
of 89.2% in Egypt.
Location of collected samples (Table 2)
Opinions overall were almost evenly divided about the
question of where collected samples should be stored,
with 32% agreeing with the statement that samples
should always be kept in the country where they were
collected and 40% disagreeing with the statement. There
were, however, marked differences between the coun-
tries, with only 10.2% in Egypt disagreeing with this
statement compared with 47.2% in Japan, and 48.8% in
Korea.
We asked two questions about specific conditions for
w h e ni tm i g h tb er e a s o n a b l et om o v es a m p l e so u to fa
country. Sometimes appropriate facilities are not avail-
able in the country of origin to do important research.
The question, however, was phrased in such a way that
we asked the respondents what they felt about this
being the only condition for transfer of samples out of
the country. In all countries, except in Korea and Japan,
a high number of respondents agreed that this should
be the only condition.
It has been proposed that a portion of the sample
could be left behind when it is necessary to do an analy-
sis outside the country. We asked respondents about
their attitude towards this policy proposal. Again, the
acceptability of such proposal was higher in the four
developing countries, compared with the respondents in
Japan and Korea.
Decisions about what research to do on stored samples
(Table 3)
We next asked about opinions regarding decision mak-
ing authority over the stored samples. When samples
are stored for future research, decisions have to be
made about what research should be done on such sam-
ples in the future. We asked respondents to consider
various alternatives, giving different levels of control
over the samples to local scientists.
The weakest involvement of local scientists would
require a consultation with them before any research is
Table 1 Numbers and percentages strongly agreeing or agreeing to the statements regarding who should receive
benefits from research on stored tissue samples
MTAs should require that, foreign collaborating scientists share royalties from discoveries,
patents and intellectual property that arises from research on the samples. ...
China
n = 154
Egypt
n = 186
India
n = 127
Japan
n = 864
Korea
n = 105
With local scientists 107
69.5%
162
87.1%
102
80.3%
430
49.8%
75
71.4%
With the population or country from which the samples were taken 95
61.7%
129
69.4%
100
78.7%
302
35%
55
52.4%
MTAs should require that the population or country from which the samples were taken is
given access to material products such as pharmaceuticals, that arise from research on the
samples
118
76.6%
166
89.2%
102
80.3%
407
47.2%
73
69.5%
Local scientists are under pressure to accept unfavorable conditions for the transfer of their
sample collections to foreign collaborating scientist with access to more resources
13
8.4%
78
42%
41
32.2%
187
21.6%
66
62.8%
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dents in all countries that this should be required, vary-
ing from a high of 92.9% in India to a low of 67.7% in
Japan.
Next we asked whether local scientists should have
some decision making power over the use of the sam-
ples. A smaller percentage of respondents in all coun-
tries agreed with this statement, varying from 90.9% in
Egypt to 56.1% in Japan.
We asked specifically whether there should be a deci-
sion making committee comprised of representatives
from the sending and the recipient countries. A high
percentage from all countries except Japan agreed with
this statement.
T h es t r o n g e s tc o n t r o lo v e rt h eu s eo ft h es a m p l eb y
local scientists would be if they have a veto power over
any use of such samples. Here there was much more
divergence of opinions, where only Egypt still had a
high percentage of respondents agreeing with this posi-
tion (83.8%), whereas in Korea 69.5%, in India 69.2%, in
China 63.7% and in Japan 47.5% agreed with this
proposal.
Finally, we asked whether local scientists should
always be included on any future protocol team. Here
again, there was wide agreement in all countries, but
with lower percentages agreeing in Japan (52.9%), and
Korea (66.2%) than in the other countries, with the
highest again being Egypt (87.1%).
Issues of authorship (Table 4)
We asked how collaborating scientists should handle the
issue of authorship. Specifically, we asked how Material
Transfer Agreements should handle this issue. Table 4
gives the results regarding these questions. We obtained
a range of answers from the respondents in different
countries. Regarding the question whether local scien-
tists should be authors on all papers arising from
research on the samples, the agreement ranged from a
high of 78.5% in Egypt to a low of 22% in Japan, with
around half agreeing in China, India and Korea. There
was a higher degree of agreement in all countries,
except Korea, on whether local scientists should be the
author on the first paper arising from the research, ran-
ging from a high of 60.4% in China to a low of 27.6% in
Japan. There was general agreement in all countries that
scientists should only be authors if they provide enough
intellectual input to the publication, ranging from a high
of 60.4% in China to a low of 43% in Japan.
Finally, we asked the question whether the respon-
dents thought that MTAs should require that local
scientists be given the opportunity to provide sufficient
intellectual input so that it would be justified to credit
them for authorship. There was overwhelming agree-
ment regarding such a requirement, ranging from 90.9%
in Egypt to 51.5% in Japan.
There are some differences in the answers to these
questions with regard to experience with MTAs. For
Table 2 Numbers and percentages strongly agreeing or agreeing to the statements regarding where stored tissue
samples should be located
China
n = 154
Egypt
n = 186
India
n = 127
Japan
n = 864
Korea
n = 105
Samples should always be kept in the country where they were collected 60
38.9%
150
80.6%
61
40.1%
170
19.7%
32
30.4%
Samples should only be transferred when research facilities are unavailable in the country of
origin
91
59.1%
142
76.3%
99
78%
192
22.2%
45
42.9%
If samples are removed, a portion must be left behind so that local scientists can use them
for their own research, unless special government permission is granted
122
79.2%
149
80.1%
105
82.7%
369
42.7%
60
57.2%
Table 3 Numbers and percentages strongly agreeing or agreeing to the statements regarding how decisions for future
research should be made
China
n = 154
Egypt
n = 186
India
n = 127
Japan
n = 864
Korea
n = 105
MTAs should require that foreign collaborating scientists consult local scientists before any
new use of samples
138
89.6%
170
91.4%
118
92.9%
1011
67.7%
82
78.1%
MTAs should require local scientists to have some decision making power over the future
use of samples
132
85.7%
169
90.9%
108
85%
484
56.1%
76
72.3%
MTAs should require that decisions regarding future use of samples should be made jointly
by a committee composed of representatives of both local and foreign scientists
110
71.4%
162
87.1%
106
83.5%
461
53.4%
72
68.5%
MTAs should require that local scientists have veto power over any future use of samples by
foreign collaborating scientists
98
63.7%
156
83.8%
88
69.2%
410
47.5%
73
69.5%
MTAs should require that a local scientist is involved in the protocol development team for
any future research on the samples
130
84.4%
165
88.7%
103
81.1%
457
52.9%
70
66.2%
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u s eo fM T A sa sar e c e i v e ro fs a m p l e s ,o n l y3 3 . 3 %a g r e e
that local scientists should be authors on all papers aris-
ing from the samples, whereas this agreement is at
49.3% among those who have been involved in the
transfer of samples. Among those who have been
involved in the development of MTAs there is an inter-
mediate agreement at 36.2%.
Legally binding regulations and role of local scientists
We asked questions about respondent attitudes towards
binding regulations regarding rights of local scientists.
Again, there was general agreement that binding regula-
tions should be in place to ensure that the rights of
local scientists are protected, ranging from 50.5% in
Japan, 76.6% in China, 81% in Korea, 89% in India, and
95.1% in Egypt. We asked who should keep these regu-
lations to protect local scientists. Here there was a wide
divergence between countries. Around half of respon-
dents in all countries, except India where only 20%
agreed, thought that the World Health Organization
should do so. Most countries, except Japan, thought
that either the local government or the local institution
should do so. In Egypt, most favored the local institu-
tion, rather than the local government.
Finally, we asked the question about their perception
regarding pressure to accept unfavorable conditions
when negotiating MTAs. For all countries except Korea,
few respondents agreed that local scientists are under
pressure to accept unfavorable conditions for the trans-
fer of samples, ranging from a low of 8.4% in China to
high of 62.8% in Korea, with Japan, Egypt and India ran-
ging from 21.6% to 42%.
Discussion
T h ec h o i c eo fc o u n t r i e sf o rt h i ss u r v e yw a sn o tm o t i -
v a t e db yad e s i r et oe x p l a i nt h ec o n t r o v e r s yo v e ra c c e s s
to a pandemic flu vaccine. Nevertheless it is interesting
to note how the responses in our survey map the posi-
tions taken by representative countries in the current
controversy over access to pandemic flu vaccines. Our
study demonstrates broad agreement for the developing
country position in the current controversy over SMTAs
within the PIP framework. The respondents would want
IP rights to be shared with researchers or the source
country, and favor access to products resulting from
research on the samples. This is, not surprisingly, most
evident among developing country researchers, where as
many as 80% are in favor of these positions. But the
support is also surprisingly high in Japan, a representa-
tive of a developed country, where 35% think that royal-
ties should be shared with the population of the source
country. 47% of our Japanese respondents believe that
MTAs should require that the source country should be
given access to material products such as pharmaceuti-
cals. If our data are representative of the positions taken
by researchers and ethics review committee members in
these countries, it indicates that there is no broad agree-
ment for the position taken by developed countries in
the ongoing debate within WHO.
Developed countries, primarily represented by the EU
and the US, have consistently taken the position during
the debate within WHO that SMTAs should not contain
legally binding benefit arrangements nor restrictions on
IP rights. At most, there can be reference to guidelines
that suggest appropriate benefits to source countries [8].
Even the so-called “middle position” suggested by the
WHO secretariat has consistently sided with developed
countries in this regard. The rationale for this position
is that strong IP rights are necessary to motivate vaccine
R&D, which ultimately will benefit developing countries.
Developing country representatives have consistently
complained that their views have not been adequately
incorporated into the drafts of the SMTAs, and have
maintained that they should contain legally binding ben-
efit arrangements and should not allow recipients of
samples to pursue IP rights on products developed
using the samples. The rationale for this position is that
the recent experience with the H1N1 pandemic has
demonstrated that pandemic flu vaccines are accessible
Table 4 MTAs should require that, in exchange for providing the samples, local scientists are credited for authorship
China
n = 154
Egypt
n = 186
India
n = 127
Japan
n = 864
Korea
n = 105
On all publications arising from research on the samples 65
42.2%
146
78.5%
74
58.3%
190
21%
51
48.6%
On the first publication arising from research on the samples 93
60.4%
101
54.3%
52
40.9%
239
27.6%
43
41%
Only if local scientists provide sufficient intellectual input into the publication 93
60.4%
90
48.4%
76
59.8%
371
43%
59
56.2%
MTAs should require that local scientists be given the opportunity to provide sufficient
intellectual input to be credited for authorship on publications arising from research on the
samples
113
73.3%
169
90.9%
110
86.6%
445
51.5%
63
60%
Numbers and percentages strongly agreeing or agreeing to the statements regarding how decisions for authorship on papers arising from the research should
be decided.
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countries have been secured [9]. Our data demonstrate
considerable sympathy for the developing country posi-
tion among our respondents.
Although IP issues and access to material benefits
have been the focus of discussion within the PIP frame-
work during World Health Assembly (WHA) meeting
during the past couple of years, developing countries
have also voiced other concerns in the debate, although
these have not been discussed as extensively. For exam-
ple, according to the WHA resolution 60.28 in 2007,
SMTAs should be based on the principles of “increased
involvement, participation, and recognition of contribu-
tion of scientists from originating country in research
related to viruses and specimens and attribution of the
work and increased co-authorship of scientists from ori-
ginating countries in scientific publications” [1]. Follow-
ing up on this resolution, a proposal from Thailand
specified that before publication of results of research
on donated samples, the source country should be con-
sulted and not object to the publication [10]. Similarly, a
proposal from several African countries also required
prior informed consent from the donating country, as
well as a requirement of involvement of source country
researchers in the execution of the research and publica-
tion of results [11]. None of these proposals have been
followed up by the WHO secretariat.
Our data again support the positions taken by these
countries (table 3). For example, a substantial number
of our respondents favor an essential veto power of the
source country over any future use, ranging from 47.5%
in Japan to 83.8% in Egypt. This very restrictive position
is in line with the suggestion by developing country that
the source country will have to approve any research
publication arising out of the use of the samples. There
is even wider agreement for more moderate positions,
such as involving local scientists in protocol develop-
ment, or jointly deciding which research should be done
on the samples.
Interestingly, our respondents also favor legally bind-
ing regulations for the transfer of samples to protect the
rights of local scientists. Representatives from develop-
ing countries have insisted throughout the discussion on
the PIP framework that SMTAs should include legally
binding provisions for benefit arrangements as well as
restrictions on IP rights. In contrast, developed coun-
tries and to a certain extent the WHO secretariat have
insisted that benefit arrangements and IP rights should
only be referred to in guidelines. This basic disagree-
ment has to a certain extent paralyzed the negotiations,
where each side insists on maintaining their positions.
Our data demonstrate widespread sympathy for the
developing country position among our respondents.
T h ed e b a t eo v e rS M T A si nt h ec o n t e x to fP a n d e m i c
Influenza Preparedness and the results from our survey
raise the question of how one should move the agenda
forward and deal with the impasse reached in the nego-
tiations. Two points seem especially important.
One the one hand, some of the suggestions from
developing countries and our respondents for specific
provisions in an SMTA seem difficult to defend. For
example, it does not seem justifiable to demand that
source countries or local scientists should have veto
rights over any publications resulting from use of stored
tissue samples. At least sometimes, this could be analo-
gous to a sponsor, such as a pharmaceutical company,
requiring collaborating scientists to sign agreements
where they can only publish after consent of the spon-
sor, leading to a justifiable criticism that this could lead
the sponsor to suppress results unfavorable to the spon-
sor. Similarly, what restrictions one should place on IP
rights seem to a large extent to be a matter of what
mechanism is best suited to stimulate innovations of
products that will have major health benefits. Although
there will be disagreements about specifics, it should be
possible to have a discussion of the merits of various
proposals.
On the other hand, it does not seem prudent for
developed countries to insist that substantive provisions
for benefits should be kept out of SMTAs. Developing
countries have continued to insist on their inclusions
but their position has been rejected by developed coun-
tries and the secretariat. The WHO secretariat should
probably recognize the widespread support of the posi-
tion taken by developing countries, which is also evident
from the data in our survey. Previous surveys in Europe
have documented considerable worries about commer-
cialization of research on stored samples, both among
those involved in biobanks [4] as well as among the gen-
eral population [12]. Rather than therefore to reject the
inclusion of binding benefit arrangements in the SMTA,
the starting point should be their inclusion. Once the
principle has been accepted, one can start on working
out the details of the provisions.
This study has several limitations. First, we assessed
the choices of survey respondents, most of whom were
a sample of convenience. As a result, our findings may
be biased toward particular groups of samples and may
not be generalizable to other populations or other coun-
tries. Second, the small sample of developed and devel-
oping countries. surveyed may not be generalizable to
developed and developing countries as a whole, respec-
tively. Finally, since we did not probe for reasons for
answers from the respondents, it is unclear whether the
respondents had motivations besides those mentioned in
the discussion for answering as they did.
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In conclusion, this study demonstrates that there here is
substantial agreement amongst all respondents to favor
some rights for local scientists and to share in the bene-
fits of research. As seen in the Indonesian case and else-
where, answers for how to arrive at an agreement for
elements of MTAs are urgently needed. Our data also
show that there is wide variation in attitudes on this
subject between countries and professional groups. This
points to a need to explore the sources of disagreement
and to develop a coherent framework for understanding
benefit sharing and elements of MTAs.
When moving forward it may also be important not to
focus exclusively on the most difficult parts, namely guar-
anteed access to product developed using provided tissue
samples or issues of IP rights. As the discussion within
WHO and the responses to our survey show, there are
other contentious issues as well: who decides and based
on what criteria does one decide how the samples should
be used, and who should receive credits on publications
arising out of the research. Specific proposals have been
put forward by a variety of developing countries, but
have not been taken up in the discussion. Interestingly,
these are also issues that are unresolved for tissue banks
established in developed countries. A recent report com-
missioned by the UK Medical Research Council and the
Wellcome Trust recommended that a standardized
access policy to sample collections be developed [5].
Recently, the UK National Cancer Research Institute has
developed a template for agreements regarding access
policies for tissue banks, after an extensive consultation
process [13]. The template covers issues such as condi-
tions for dissemination of results of research. Developing
a similar framework within the international context
such as PIP could build on these efforts, and they demon-
strate that some agreement is possible.
Additional material
Additional file 1: Surveyinstrument. This file contains the survey
instrument.
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